2021
DOI: 10.3389/fmed.2021.731436
|View full text |Cite
|
Sign up to set email alerts
|

Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review

Abstract: Introduction: The severity of COVID-19 may be correlated with the risk of liver injury development. An increasing number of studies indicate that degrees of hepatotoxicity has been associated with using some medications in the management of COVID-19 patients. However, limited studies had systematically investigated the evidence of drug-induced liver injury (DILI) in COVID-19 patients. Thus, this study aimed to examine DILI in COVID-19 patients.Methods: A systematic search was carried out in PubMed/Medline, EMB… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
66
0
4

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 53 publications
(78 citation statements)
references
References 98 publications
0
66
0
4
Order By: Relevance
“…Recently, there has been a great correlation between SARS-CoV-2 severity and hepatotoxicity especially induced by antibiotics. The severity of COVID-19 may be related with the risk of liver injury development [15]. There is increasing evidence that indicates that hepatotoxicity has been associated with the use of some medications in the treatment of patients infected with SARS-CoV-2 during the COVID-19 pandemic [15].…”
Section: Synthesismentioning
confidence: 99%
See 1 more Smart Citation
“…Recently, there has been a great correlation between SARS-CoV-2 severity and hepatotoxicity especially induced by antibiotics. The severity of COVID-19 may be related with the risk of liver injury development [15]. There is increasing evidence that indicates that hepatotoxicity has been associated with the use of some medications in the treatment of patients infected with SARS-CoV-2 during the COVID-19 pandemic [15].…”
Section: Synthesismentioning
confidence: 99%
“…The severity of COVID-19 may be related with the risk of liver injury development [15]. There is increasing evidence that indicates that hepatotoxicity has been associated with the use of some medications in the treatment of patients infected with SARS-CoV-2 during the COVID-19 pandemic [15]. Recent epidemiological studies indicate different degrees of elevated liver hepatic enzymes with an incidence of 24.4%, particularly in liver transaminases, AST and ALT in COVID-19 patients.…”
Section: Synthesismentioning
confidence: 99%
“…Furthermore, COVID-19 is a systemic disease that can present many complications, including liver injury as result of CRS in severe COVID-19 infection. This liver disorder would increase the susceptibility to DILI in the pharmacotherapy of COVID-19 patients ( Sodeifian et al, 2021 ).…”
Section: Introductionmentioning
confidence: 99%
“…Although tocilizumab is an effective treatment for hypoxia, it is a risky agent in terms of its side-effect profile. In particular, the risk of hepatotoxicity has been previously reported [ 17 , 18 ]. Therefore, the CO-RADS classification can be used as a parameter in determining treatment indication together with saturation values.…”
Section: Discussionmentioning
confidence: 99%